An official website of the United States government
Reported Tuberculosis in the United States, 2021
Table 18. Percentages of Tuberculosis Cases by Initial Drug Regimen, Method of Administration, and Completion of Therapy (COT): United States, 1993–2021
See Surveillance Slides #42, #43, #44, #45 and #46.
| Year | Total cases1 | Initial drug regimen2 | Method of administration3, 4 | Therapy ≤1 year indicated5 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HRZE6 | Multi (4+) drug regimen7 | No. | DOT only | Both DOT and SAT | No. | COT ≤1 year | COT ever | ||||||||
| No. | (%) | No. | (%) | No. | (%) | No. | (%) | No. | (%) | No. | (%) | ||||
| 2021 | 7,604 | 6,330 | (83.2) | 794 | (10.4) | –– | –– | –– | –– | –– | –– | –– | –– | –– | –– |
| 2020 | 6,955 | 5,801 | (83.4) | 745 | (10.7) | –– | –– | –– | –– | –– | –– | –– | –– | –– | –– |
| 2019 | 8,665 | 7,177 | (82.8) | 1,017 | (11.7) | 8,632 | 5,241 | (62.2) | 2,778 | (33.0) | 7,189 | 6,460 | (89.9) | 6,863 | (95.5) |
| 2018 | 8,786 | 7,287 | (82.9) | 1,029 | (11.7) | 8,738 | 5,269 | (61.2) | 2,903 | (33.7) | 7,355 | 6,574 | (89.4) | 7,048 | (95.8) |
| 2017 | 8,886 | 7,450 | (83.8) | 925 | (10.4) | 8,843 | 5,357 | (61.2) | 2,875 | (32.8) | 7,394 | 6,686 | (90.4) | 7,132 | (96.5) |
| 2016 | 9,019 | 7,669 | (85.0) | 913 | (10.1) | 8,977 | 5,660 | (63.9) | 2,701 | (30.5) | 7,575 | 6,768 | (89.3) | 7,262 | (95.9) |
| 2015 | 9,313 | 7,951 | (85.4) | 859 | (9.2) | 9,281 | 5,997 | (65.0) | 2,625 | (28.5) | 7,852 | 7,083 | (90.2) | 7,577 | (96.5) |
| 2014 | 9,174 | 7,831 | (85.4) | 838 | (9.1) | 9,148 | 5,786 | (63.8) | 2,645 | (29.1) | 7,709 | 6,959 | (90.3) | 7,467 | (96.9) |
| 2013 | 9,295 | 7,860 | (84.6) | 887 | (9.5) | 9,259 | 5,753 | (63.2) | 2,620 | (28.8) | 7,762 | 6,974 | (89.8) | 7,479 | (96.4) |
| 2012 | 9,694 | 8,283 | (85.4) | 872 | (9.0) | 9,659 | 5,826 | (61.8) | 2,751 | (29.2) | 8,093 | 7,298 | (90.2) | 7,812 | (96.5) |
| 2011 | 10,216 | 8,706 | (85.2) | 825 | (8.1) | 10,175 | 6,161 | (62.3) | 2,882 | (29.1) | 8,463 | 7,594 | (89.7) | 8,167 | (96.5) |
| 2010 | 10,802 | 9,127 | (84.5) | 875 | (8.1) | 10,752 | 6,315 | (59.3) | 3,304 | (31.0) | 9,049 | 8,107 | (89.6) | 8,696 | (96.1) |
| 2009 | 11,222 | 9,466 | (84.4) | 872 | (7.8) | 11,159 | 6,603 | (59.7) | 3,344 | (30.2) | 9,494 | 8,434 | (88.8) | 9,077 | (95.6) |
| 2008 | 12,679 | 10,678 | (84.2) | 965 | (7.6) | 12,602 | 7,038 | (56.5) | 4,165 | (33.4) | 11,068 | 9,532 | (86.1) | 10,333 | (93.4) |
| 2007 | 12,973 | 10,874 | (83.8) | 847 | (6.5) | 12,898 | 7,192 | (56.3) | 4,214 | (33.0) | 11,406 | 9,747 | (85.5) | 10,696 | (93.8) |
| 2006 | 13,396 | 11,157 | (83.3) | 880 | (6.6) | 13,310 | 7,612 | (57.5) | 4,022 | (30.4) | 11,645 | 9,868 | (84.7) | 10,846 | (93.1) |
| 2005 | 13,754 | 11,511 | (83.7) | 689 | (5.0) | 13,666 | 7,840 | (57.9) | 4,012 | (29.6) | 11,945 | 10,029 | (84.0) | 11,045 | (92.5) |
| 2004 | 14,193 | 11,697 | (82.4) | 694 | (4.9) | 14,079 | 8,181 | (58.9) | 3,857 | (27.8) | 12,359 | 10,414 | (84.3) | 11,436 | (92.5) |
| 2003 | 14,478 | 11,775 | (81.3) | 683 | (4.7) | 14,376 | 8,051 | (56.5) | 4,056 | (28.5) | 12,641 | 10,562 | (83.6) | 11,722 | (92.7) |
| 2002 | 14,695 | 11,802 | (80.3) | 630 | (4.3) | 14,563 | 7,972 | (55.4) | 3,996 | (27.8) | 12,712 | 10,543 | (82.9) | 11,752 | (92.4) |
| 2001 | 15,536 | 12,403 | (79.8) | 606 | (3.9) | 15,407 | 8,159 | (53.7) | 4,186 | (27.5) | 13,510 | 11,141 | (82.5) | 12,521 | (92.7) |
| 2000 | 15,869 | 12,457 | (78.5) | 670 | (4.2) | 15,782 | 8,190 | (52.5) | 4,029 | (25.8) | 13,730 | 11,280 | (82.2) | 12,702 | (92.5) |
| 1999 | 16,941 | 13,019 | (76.8) | 792 | (4.7) | 16,855 | 8,182 | (49.4) | 4,572 | (27.6) | 14,659 | 11,931 | (81.4) | 13,508 | (92.1) |
| 1998 | 17,727 | 13,167 | (74.3) | 761 | (4.3) | 17,585 | 8,240 | (47.7) | 4,594 | (26.6) | 15,230 | 12,370 | (81.2) | 14,040 | (92.2) |
| 1997 | 19,063 | 13,714 | (71.9) | 828 | (4.3) | 18,932 | 8,702 | (47.0) | 4,411 | (23.8) | 16,326 | 12,849 | (78.7) | 14,861 | (91.0) |
| 1996 | 20,424 | 13,750 | (67.3) | 894 | (4.4) | 20,300 | 8,437 | (42.5) | 4,452 | (22.4) | 17,412 | 13,369 | (76.8) | 15,711 | (90.2) |
| 1995 | 21,850 | 13,704 | (62.7) | 1,058 | (4.8) | 21,706 | 7,856 | (37.3) | 4,532 | (21.5) | 18,454 | 13,671 | (74.1) | 16,461 | (89.2) |
| 1994 | 23,197 | 12,925 | (55.7) | 1,287 | (5.5) | 23,053 | 6,190 | (28.1) | 4,528 | (20.5) | 19,452 | 13,343 | (68.6) | 16,890 | (86.8) |
| 1993 | 23,964 | 9,664 | (40.3) | 1,185 | (4.9) | 23,743 | 5,052 | (21.7) | 3,355 | (14.4) | 19,899 | 12,621 | (63.4) | 17,115 | (86.0) |
1Persons alive at diagnosis with initial drug regimen information.
2In the 50 U.S. states, New York City, and District of Columbia: In 2021, 70 (0.9%) received no initial drug therapy and 20 (0.3%) were started on one drug.
3Persons on an initial drug therapy with at least one drug.
4DOT, directly observed therapy; SAT, self-administered therapy.
5Excludes patients who died within one year of initiating therapy; patients with an initial isolate resistant to rifampin; patients with bone and joint disease, meningeal disease, or disease of the central nervous system; or patients <15 years of age with miliary disease, positive blood culture, or a positive nucleic acid amplification test on a blood specimen. Beginning in 2011, patients who moved out of the country within one year of initiating therapy were also excluded.
6H, isoniazid; R, rifampin; Z, pyrazinamide; E, ethambutol.
7A drug regimen with at least four drugs, other than HRZE.
Note: Data for all years are updated through July 8, 2022.
Double dashes (––) indicate that data are not available.
See Technical Notes